Press Releases

——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
New Published Data Point to Spike Protein Interactions with Estrogen Receptors as a cause for Coagulopathy in Covid-19 Patients, Signaling Sex Effects and a Path to Improved Vaccines
Two Clinical Studies to Treat Mild-to-Moderate COVID-19 at Home Reveal Value of Exscalate, Dompé’s AI Platform for Drug Design
Dompé Announces Results of Phase 2 Study Evaluating the Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia
Dompé Further Elevates Commitment to Ophthalmics with Industry-Leading Hires
Dompé announces first patient enrolled in Phase 3 trial of cenegermin in patients with severe Sjögren's-related dry eye disease
Dompé Farmaceutici S.P.A Announces Strategic Investment and Collaboration with Engitix Positioned Around Use of Dompé’s Exscalate Drug Discovery Platform
Dompé-Substipharm agreement for the sale of 6 brands
Dompé Announces Activation of U.S. Clinical Trial Sites for Phase 3 Study of Reparixin, an Oral Investigational CXCR1/CXCR2 Inhibitor, in Hospitalized Patients with Severe COVID-19 Pneumonia
Leonardo and Dompé launch the first, national digital health security infrastructure with Cloud architecture
LIGATE: NEW EUROPEAN BACKED EFFORT AGAINST PANDEMICS KICKS OFF WITH 5,9 MLN €
Dompé Announces First Patient Enrolled in Phase 3 trial of Ladarixin, an Oral Investigational CXCR1/2 Inhibitor, in New-Onset Type 1 Diabetes (T1D)
DOMPÉ AND THE FARMAMONDO GROUP: EXCLUSIVE AGREEMENT TO DISTRIBUTE OXERVATE™ IN RUSSIA AND OTHER CIS COUNTRIES